Compounds for targeting cancer stem cells

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11427543
APP PUB NO 20210238140A1
SERIAL NO

16318846

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This invention relates to antagonists of G3BP2, G3BP1, and ZEB1. Pharmaceutical compositions comprising G3BP2 inhibitors, methods of inhibiting G3BP2, G3BP1, and ZEB1, methods of treating cancer and inflammation, and methods of identifying an inhibitor of cancer stems cells are also provided.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
THE GENERAL HOSPITAL CORPORATION55 FRUIT ST BOSTON MA 02114

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Garkavtsev, Igor Cambridge, US 11 54
Jain, Rakesh K Wellesley, US 48 354

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Feb 28, 2026
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 28, 2030
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 28, 2034
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00